CYP19A1 and breast cancer: The mechanism of action of AIs, such as exemestane, anastrozole, and letrozole, is the inhibition of the production of the ER ligand, leading to the inhibition of the aromatase enzyme and therefore allowing the reduction of estrogen levels with consequent benefit for BC patients in their treatment journey.